Asad Haider
Stock Analyst at Goldman Sachs
(2.82)
# 1,667
Out of 5,138 analysts
15
Total ratings
85.71%
Success rate
16.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $115 → $142 | $105.56 | +34.52% | 2 | Jan 16, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $218.21 | +9.99% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $32.41 | +14.16% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $54.22 | +5.13% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $19.55 | -13.04% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $39.09 | +7.44% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $47.52 | -20.03% | 1 | Sep 12, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $1,041.29 | -14.72% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $214.04 | -9.36% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $25.52 | -2.04% | 1 | Apr 8, 2025 |
BioNTech SE
Jan 16, 2026
Upgrades: Buy
Price Target: $115 → $142
Current: $105.56
Upside: +34.52%
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $218.21
Upside: +9.99%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $32.41
Upside: +14.16%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $54.22
Upside: +5.13%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $19.55
Upside: -13.04%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $39.09
Upside: +7.44%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $47.52
Upside: -20.03%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $1,041.29
Upside: -14.72%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $214.04
Upside: -9.36%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $25.52
Upside: -2.04%